Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer

Detalhes bibliográficos
Autor(a) principal: Silva,Fernando Marcuz
Data de Publicação: 2001
Outros Autores: Zaterka,Schlioma, Eisig,Jaime Natan, Chehter,Ethel Zimberg, Chinzon,Décio, Laudanna,Antonio Atílio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Hospital das Clínicas
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812001000100003
Resumo: Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy. METHODS: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection (histology and rapid urease test - RUT) were included. A proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg), tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10 to 12 weeks of treatment through histology and RUT. RESULTS: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to treatment was good, and side effects were mild. CONCLUSIONS: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in 65% of the patients. Previous treatments were the main cause of treatment failure.
id USP-57_70eab0f4151009c65265067dc24bc16a
oai_identifier_str oai:scielo:S0041-87812001000100003
network_acronym_str USP-57
network_name_str Revista do Hospital das Clínicas
repository_id_str
spelling Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcerPeptic Ulcer TreatmentHelicobacter pylori EradicationProton pump inhibitorTinidazoleClarithromycinTriple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy. METHODS: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection (histology and rapid urease test - RUT) were included. A proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg), tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10 to 12 weeks of treatment through histology and RUT. RESULTS: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to treatment was good, and side effects were mild. CONCLUSIONS: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in 65% of the patients. Previous treatments were the main cause of treatment failure.Faculdade de Medicina / Universidade de São Paulo - FM/USP2001-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812001000100003Revista do Hospital das Clínicas v.56 n.1 2001reponame:Revista do Hospital das Clínicasinstname:Universidade de São Paulo (USP)instacron:USP10.1590/S0041-87812001000100003info:eu-repo/semantics/openAccessSilva,Fernando MarcuzZaterka,SchliomaEisig,Jaime NatanChehter,Ethel ZimbergChinzon,DécioLaudanna,Antonio Atílioeng2001-05-24T00:00:00Zoai:scielo:S0041-87812001000100003Revistahttp://www.scielo.br/rhcPUBhttps://old.scielo.br/oai/scielo-oai.php||revista.hc@hcnet.usp.br1678-99030041-8781opendoar:2001-05-24T00:00Revista do Hospital das Clínicas - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
title Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
spellingShingle Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
Silva,Fernando Marcuz
Peptic Ulcer Treatment
Helicobacter pylori Eradication
Proton pump inhibitor
Tinidazole
Clarithromycin
title_short Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
title_full Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
title_fullStr Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
title_full_unstemmed Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
title_sort Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in brazilian patients with peptic ulcer
author Silva,Fernando Marcuz
author_facet Silva,Fernando Marcuz
Zaterka,Schlioma
Eisig,Jaime Natan
Chehter,Ethel Zimberg
Chinzon,Décio
Laudanna,Antonio Atílio
author_role author
author2 Zaterka,Schlioma
Eisig,Jaime Natan
Chehter,Ethel Zimberg
Chinzon,Décio
Laudanna,Antonio Atílio
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Silva,Fernando Marcuz
Zaterka,Schlioma
Eisig,Jaime Natan
Chehter,Ethel Zimberg
Chinzon,Décio
Laudanna,Antonio Atílio
dc.subject.por.fl_str_mv Peptic Ulcer Treatment
Helicobacter pylori Eradication
Proton pump inhibitor
Tinidazole
Clarithromycin
topic Peptic Ulcer Treatment
Helicobacter pylori Eradication
Proton pump inhibitor
Tinidazole
Clarithromycin
description Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy. METHODS: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection (histology and rapid urease test - RUT) were included. A proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg), tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10 to 12 weeks of treatment through histology and RUT. RESULTS: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to treatment was good, and side effects were mild. CONCLUSIONS: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in 65% of the patients. Previous treatments were the main cause of treatment failure.
publishDate 2001
dc.date.none.fl_str_mv 2001-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812001000100003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812001000100003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0041-87812001000100003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
dc.source.none.fl_str_mv Revista do Hospital das Clínicas v.56 n.1 2001
reponame:Revista do Hospital das Clínicas
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista do Hospital das Clínicas
collection Revista do Hospital das Clínicas
repository.name.fl_str_mv Revista do Hospital das Clínicas - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||revista.hc@hcnet.usp.br
_version_ 1754820894072504320